1	"Learn from the lessons and don't forget them":
2	Identifying transferable lessons for COVID-19 from
3	meningitis A, yellow fever, and Ebola virus disease
4	vaccination campaigns
5	
6	Julie Collins ¹ , Rosie Westerveld ² , Kate A Nelson ² , Hana Rohan ¹ , Hilary Bower ¹ , Siobhan
7	Lazenby ³ , Gloria Ikilezi ³ , Rebecca Bartlein ³ , Daniel G Bausch ¹ , David S Kennedy ¹
8	
9	¹ UK Public Health Rapid Support Team, London School of Hygiene & Tropical

- 10 Medicine/Public Health England, London, United Kingdom
- ¹¹ ²London School of Hygiene & Tropical Medicine, London, United Kingdom
- ¹² ³Gates Ventures, Seattle, United States of America
- 13

14

- 15 **Corresponding author**
- 16 Julie Collins
- 17 UK Public Health Rapid Support Team, London School of Hygiene & Tropical
- 18 Medicine/Public Health England
- 19 Keppel Street, London WC1E 7HT, United Kingdom
- 20 Email: julie.collins@lshtm.ac.uk
- 21

23 ABSTRACT

24 Introduction: COVID-19 vaccines are now being distributed to low- and middle-income

countries (LMICs), with global urgency surrounding national vaccination plans. LMICs have

- 26 significant experience implementing vaccination campaigns to respond to epidemic threats
- 27 but are often hindered by chronic health system challenges. We sought to identify
- 28 transferable lessons for COVID-19 vaccination from the rollout of three vaccines that
- 29 targeted adult groups in Africa and South America: MenAfriVac (meningitis A); 17D (yellow
- 30 fever); and rVSV-ZEBOV (Ebola virus disease).
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

²² World count: 5,217

Methods: We conducted a rapid literature review and 24 semi-structured interviews with technical experts who had direct implementation experience with the selected vaccines in Africa and South America. We identified barriers, enablers, and key lessons from the literature and from participants' experiences. Interview data were analysed thematically according to seven implementation domains.

37

38 Results: Participants highlighted multiple components of vaccination campaigns that are instrumental for achieving high coverage. Community engagement is an essential and 39 40 effective tool, requiring dedicated time, funding and workforce. Involving local health workers is a key enabler, as is collaborating with community leaders to map social groups 41 and tailor vaccination strategies to their needs. Vaccination team recruitment and training 42 strategies need to be enhanced to support vaccination campaigns. Although recognised as 43 challenging, integrating vaccination campaigns with other routine health services can be 44 highly beneficial if well planned and coordinated across health programmes and with 45 communities. 46

47

48 Conclusion: As supplies of COVID-19 vaccines become available to LMICs, countries need 49 to prepare to efficiently roll out the vaccine, encourage uptake among eligible groups, and 50 respond to potential community concerns. Lessons from the implementation of these three 51 vaccines that targeted adults in LMICs can be used to inform best practice for COVID-19 and 52 other epidemic vaccination campaigns.

53

KEY QUESTIONS

What is already known?

- Low- and middle-income countries (LMICs) have substantial experience conducting vaccination campaigns as a part of epidemic responses.
- Vaccination campaigns in LMICs are impacted by a number of systemic challenges, including poor infrastructure, limited resources, and an overstretched health workforce.
- Meningitis A, yellow fever and Ebola virus disease vaccines have been recently
 rolled out in LMICs to respond to epidemic threats. These campaigns share some of
 the same challenges anticipated for COVID-19 vaccination, including the focus on
 adult target groups.

What are the new findings?

- Extensive community engagement is crucial when targeting adults for vaccination in LMICs to shift community perceptions that vaccination is only associated with children.
- Working with community leaders to map social groups and plan effective vaccination strategies is vital to achieving high vaccination coverage.
- Recruiting local health workers who have established links to the community, can speak the local language, and can leverage existing rapport to increase vaccination uptake, is preferred over bringing in staff from other regions.
- Vaccination training quality is reduced as information is transmitted down to lower levels using the 'cascade' or 'training-of-trainers' model. Training for vaccination campaigns in LMICs has been further affected by COVID-19 and the move to remote learning. Where access to training is limited, a greater emphasis is placed on resource-intensive supervision to ensure the effectiveness of vaccination campaigns.

What do the new findings imply?

- Previous vaccination campaigns conducted during epidemics are an important source of transferable lessons that can assist countries in their COVID-19 vaccine rollouts and future epidemic preparedness.
- Our findings suggest that countries can strengthen vaccination campaigns during epidemics by recruiting local health workers to assist vaccination teams, by providing operational funding for pre-campaign community engagement and social mobilisation activities, and by examining the effectiveness of vaccination training and developing new models where needed.
- Implementing these lessons for COVID-19, however, relies on countries having sufficient vaccine supply.

55

57 **INTRODUCTION**

58	Development and mass-production of multiple safe and effective COVID-19 vaccines have
59	progressed faster than expected. There are signs that, with high population-level vaccination
60	coverage, pre-pandemic levels of mobility and economic activity could safely resume.[1, 2]
61	However, COVID-19 vaccination has been dominated by high-income countries, which have
62	purchased 51% of vaccine doses yet represent only 14% of the global population.[3] As of 10
63	July 2021, only 1% of people in low-income countries had received at least one dose of a
64	COVID-19 vaccine.[4] Adequate vaccine supply is a critical first step. Access mechanisms,
65	such as the COVID-19 Vaccines Global Access (COVAX) initiative, have been established
66	to support vaccine supply in low- and middle-income countries (LMICs); however, modest
67	initial targets have not been met.[5] In addition to increasing access to vaccine supplies,
68	critical work is needed to ensure that vaccines reach their intended target groups.
69	
70	Many factors can complicate vaccine rollouts in LMICs, including limited health and
71	surveillance infrastructure, insufficient cold chain transportation and storage capacity, and an
72	under-resourced health workforce.[6, 7] However, some LMICs also have substantial
73	experience in conducting vaccination campaigns to prevent or respond to epidemics, from
74	which valuable lessons can be drawn for the rollout of COVID-19 vaccines.
75	
76	We examined vaccination campaigns recently conducted as part of epidemic responses
77	(hereafter, 'vaccination campaigns') in LMICs in Africa and South America. We selected
78	
	three vaccines – MenAfriVac (meningitis A), 17D (yellow fever), and rVSV-ZEBOV (Ebola
79	three vaccines – MenAfriVac (meningitis A), 17D (yellow fever), and rVSV-ZEBOV (Ebola virus disease) – that share some of the same challenges anticipated for COVID-19 in LMICs

81 COVID-19 vaccination campaigns.

Criteria	Ebola virus disease (rVSV-ZEBOV)	Yellow Fever (17D)	Meningitis A (MenAfriVac)
Cold chain requirements	-70°C	2-8°C [61]	2-8°C[62]
Dose regimen	Single Dose	Single Dose	Single Dose[63]
Target populations during outbreak- related campaigns	Adults aged ≥18 years.* Healthcare workers, contacts of confirmed cases & contacts of contacts.	Children and adults [†] aged ≥9 months[61]	Children and adults aged 1 – 29 years[63]
Regions	Democratic Republic of Congo, Burundi, Guinea, Liberia, Sierra Leone, Rwanda, Uganda	Africa and South America	"Meningitis belt" in Africa – sub-Saharan Africa from Senegal to Ethiopia [62]
Year	2019[64]	1927[61]	2010[62]
developed/licenced			
Key similarities with COVID-19 Vaccines	Primarily targeted adults; required ultra-cold chain management	Targeted adults as well as children	Targeted adults as well as children

82 **TABLE 1: Characteristics of the selected vaccines**

83 *Children aged 6–17 years also included in some Phase 1 to 3 trials[65]; Children >6 months were included in

84 the 2018–2020 outbreak in Democratic Republic of Congo under compassionate use protocol.[66]

85 [†]*Upper limit age group varied by outbreak.*

87 **METHODS**

- 88 We conducted a rapid literature review followed by semi-structured interviews with technical
- 89 experts to identify barriers, enablers, and lessons from implementing the three vaccines in
- 90 recent outbreaks in Africa and South America.

91

- 92 We designed a thematic framework of seven domains (Table 2) to guide the research, based
- on existing vaccine readiness assessment tools and gap analyses developed for implementing
- Ebola virus disease (EVD) vaccines[8, 9] and COVID-19 vaccination guidelines developed
- 95 by the World Health Organization (WHO).[10]

96

Do	main	Description
1)	Planning and coordination	Macro/microplanning; funding; vaccination campaign management; decision-making; coordination and communication mechanisms; stakeholder engagement; stakeholder roles; policy and regulatory framework.
2)	Target groups and delivery strategies	Target group inclusion and exclusion criteria; prioritisation of groups; communication of target groups; delivery strategies for vaccination (e.g., house-to-house, fixed post, mobile fixed post); tailoring of delivery strategies to reach sub-groups.
3)	Logistics and supply	Supply chain; infrastructure; vaccine storage; cold chain (and ultra-cold chain) management; transportation; equipment (including personal protective equipment); waste disposal.
4)	Vaccination teams	Team composition and roles; recruitment; training techniques and processes; team coordination and communication.
5)	Vaccination monitoring and safety surveillance	Identifying cases of disease and differentiating between similar pathogens; recording, reporting and monitoring vaccination coverage; identification, reporting and management of adverse events following immunisation; use of technology.
6)	Community engagement and social mobilisation ¹	Developing relationships with communities and working together to conduct vaccination activities; strategies to increase vaccine demand and uptake, including communication strategies.
7)	Vaccine confidence ²	Perceptions and attitudes toward the vaccine; factors contributing to confidence or resistance; types of rumours and misinformation; strategies to address rumours and misinformation.

98 **TABLE 2: Thematic framework for the implementation of vaccines**

¹World Health Organization definitions of community engagement and social mobilisation were used in this
 research, however it was noted that these terms were often used interchangeably by key informants.[67, 68]

² Vaccine confidence was not identified in articles retrieved in the literature review but was discussed in the key
 informant interviews.

103

105 Literature review

106	We searched Embase, MEDLINE & Global Health databases in early February 2021.
107	Searches were not restricted by location, year of publication or language. Search terms are
108	provided in Appendix 1. For inclusion, articles were required to 1) focus on an LMIC in
109	Africa or South America, and 2) describe the implementation of one of the selected vaccines.
110	Following de-duplication, we conducted title and abstract screening, followed by full-text
111	screening. Texts meeting these criteria were cross-referenced to identify additional relevant
112	papers for inclusion. Data were extracted from the included articles according to the thematic
113	framework (Table 2).
114	

115 Key informant interviews

116 Participants

Using a purposive sampling approach, we identified technical experts through the professional networks of the research team and via "snowball sampling." Participants had either 1) involvement in the rollout of one or more of the selected vaccines through global initiatives or organisations, or 2) implementation experience with one or more of the selected vaccines at either a regional, national, or sub-national level.

122

123 Data collection

We developed a semi-structured interview guide, based on preliminary findings from the literature review and using the thematic framework (Table 2). The interview guide helped elicit specific information across the domains but was sufficiently flexible to allow the interview to be guided by the participants' experiences. While the interviews focused on the three selected vaccines, interviewers did not dissuade participants from drawing on their

129	experiences from other campaigns. Participants were given the opportunity to reflect on their
130	experiences with the initial COVID-19 vaccination rollout, where appropriate.
131	
132	Interviews were conducted virtually via Zoom and were in either English or French.
133	Interviews were digitally recorded, professionally translated to English when required, and
134	transcribed. The interviewers verified each transcript to ensure accuracy before commencing
135	data analysis.
136	
137	Data analysis
138	We analysed the qualitative data thematically, using deductive and inductive coding in Nvivo
139	12 Plus. A coding framework was developed based on the seven domains in the thematic
140	framework (Table 2), along with additional themes emerging from the data. Key trends,
141	barriers, enablers, and lessons shared by participants were identified across each theme.
142	
143	RESULTS

144 Literature review

145 Thirty-seven studies met the inclusion criteria (Figure 1): 15 meningitis A[11-25]; 11 Ebola

virus disease[26-36]; eight yellow fever[37-44]; one meningitis A and yellow fever[45]; and

147 two focusing on general vaccination strategies.[46, 47] Twenty-eight studies focused on

African countries[11-35, 40, 44, 46, 47]; two on South American countries[41, 43]; and six

studies did not specify a region[36-39, 42, 45] (Table 3).

150

152 **TABLE 3: Studies identified through the literature review**

Author	Year	Disease			Location			
		Meningitis A	Ebola	Yellow fever	General	Africa	South America	Global
Aguado, M.T., et al.[11]	2015	X				X		
Burchett, H.E.D., et	2014	Х				Х		
al.[12] Marchetti, E., et al.[13]	2012	х				Х		
Zipursky, S., et al.[14]	2012	X				X		
Djingarey, M.H., et al.[15]	2012	X				X		
Cibrelus, L., et al.[16]	2015	Х				Х		
Okwo-Bele, J.M. et al.[17]	2011	Х				Х		
Tartof, S., et al.[18]	2013	Х				Х		
Mbaeyi, S., et al.[19]	2020	Х				Х		
Daugla, D.M., et al.[20]	2014	Х				Х		
Nkwenkeu, S.F., et al.[21]	2020	X				X		
Patel, J.C., et al.[22]	2019	X				X		
Diomande, F.V.K., et al.[23] Berlier, M., et al.[24]	2015 2015	X X				X X		
Djingarey et al.[25]	2015	X				X		
Ughasoro, M.D., et	2015	А	Х			X		
al.[26]	2013		X			X		
Wolf, J., et al.[27] Jusu, M.O., et al.[28]	2020		X X			X		
Jusu, M.O., et al.[28] Samai, M., et al.[29]	2018		л Х			X X		
Dean, N.E., et al.[30]	2018		X			X		
Hossmann, S., et al.[31]	2019		X			X		
Grantz, K.H., et al.[32]	2019		X			X		
Juan-Giner, A., et al.[33]	2019		X			X		
Elemuwa, C., et al.[34]	2015		Х			Х		
Alenichev, A. et al.[35]	2020		Х			Х		
Folayan, M.O., et al.[36]	2016		Х					Х
Tomashek, K., et al.[37]	2019			Х				Х
Chen, L.H. et al.[38]	2017			Х				Х
Vannice, K. et al.[39]	2018			Х				Х
Barrett, A.D.T. et al.[40]	2016			X		Х	37	
Possas, C., et al.[41]	2018			X			Х	37
Martins, R.M., et al.[42]	2013			X			17	Х
Flamand, C., et al.[43]	2019			X		v	Х	
Legesse, M., et al.[44]	2018	v		X		Х		v
Nguyen, T. et al.[45]	2019	X		Х	v	V		Х
Yakum, M.N., et al.[46]	2015				X	X		
Sow, C., et al.[47]	2018				Х	Х		

154 Key informant interviews

- 155 Twenty-four key informants were interviewed from late February to late April
- 156 2021. Participants included health professionals and technical officers working for national
- 157 health agencies, multilateral organisations (including United Nations agencies), non-
- 158 governmental organisations (NGOs), and academia. All participants had worked with at least
- 159 one of the selected vaccines in LMICs, with 23 reflecting on their vaccination campaign
- 160 experiences across West, Central and East Africa, and one on their experiences in South
- 161 America. Sixty-three per cent of participants were male (15/24). The average interview length
- 162 was one hour (range 40–80 minutes).
- 163

164 Key lessons for COVID-19 vaccination

We present findings from the literature review and qualitative interviews together, according to the thematic framework. Illustrative quotes have been included along with the participant's organisation type and regions where they worked with the selected vaccines.

168

1) Planning and coordination

169 *Early engagement with diverse stakeholders to support campaign planning*

Successful vaccination campaigns engage early with a broad network of stakeholders to support detailed pre-campaign planning. Collaboration with other government departments (e.g., Ministries of Education, Finance, and Transport) was considered crucial by interview participants, since health teams often relied on their support to conduct activities. Involving staff at the health facility level was critical to understand context, geography and social nuances within their catchment area.

For the success of the campaign, we must have a strong microplan, originating from the health facility itself that is going to be involved. ... [without this] you may still

178	succeed in the vaccination coverage, but you will have a lot of hurdles. (National
179	health agency, East Africa)

180 While participants noted the time pressures of reactive vaccination campaigns, the

181 importance of engaging and planning with health facility staff and communities before

182 commencing vaccination was consistently emphasised.

183

184 International partners, such as multilateral organisations, NGOs, and civil society

185 organisations, play a key role in supporting campaign resourcing and implementation.

186 Disease-specific initiatives, such as the Meningitis Vaccine Project and the Eliminate Yellow

187 Fever Epidemics strategy, have assisted with access to vaccines, supported vaccine

188 implementation and promoted mutual learning between countries.[13] However, participants

did raise concerns about the sustainability of mass vaccination activities without such

190 external support.[23-25]

191

192 COVAX and other initiatives are working to improve access to COVID-19 vaccines for
 193 LMICs. Still, some participants called attention to a gap in operational funding needed to
 194 support vaccination activities, such as community engagement.

As long as the funds for operations are available, then it will be much easier for us to
 roll out any vaccine activity. ... Fine, you are giving us the vaccine free of charge, but
 you should also factor in the operational costs. (Multilateral organisation, East Africa)
 Insufficient operational funding has impaired some countries' capacity to conduct preparatory
 activities for COVID-19 vaccination campaigns, such as raising awareness and encouraging
 vaccine uptake among health workers; participants were apprehensive about vaccine uptake
 in the absence of such activities.

204 *Establishing strong coordination mechanisms*

Robust coordination mechanisms are necessary to provide direction and oversight over
campaign activities. Participants highlighted the benefits of an incident management system
(IMS) that delineates the roles and responsibilities of government departments (e.g., disease
control, routine immunisation, national drug authorities) and partner organisations and
prevents the duplication of response efforts.

- 210 [The IMS] helped us to coordinate the partners, because at the beginning of Ebola in
- 211 West Africa, everybody took the money, went into the community without asking the
- others. [It was a] nightmare, until we found this coordination mechanism, this
- harmonisation of all the priorities in one single strategic response plan. (Multilateral
- 214 organisation, West and Central Africa)

215 Within the IMS, technical working groups (e.g., logistics, social mobilisation) can foster

collaboration between health agencies and international partners. In relation to COVID-19,

some participants outlined how they were drawing on the strength of previously established

- technical working groups to conduct rapid vaccination preparations. The need for effective
- communication both within and between working groups was emphasised during interviews.

220 Regarding EVD vaccination campaigns, some participants highlighted how the 'industry' of

the outbreak led to competition and fragmentation. Different response teams (e.g., contact

tracing and vaccination teams) vied to demonstrate their unique contributions and retain high-

- 223 paying positions.[32]
- 224

2) Target groups and delivery strategies

225 *Target groups and community perceptions*

Vaccinating adults requires a shift in community understandings of vaccination, which are traditionally associated with children. Perceptions and suspicions around adult target groups need to be recognised and accounted for in vaccination planning. Participants highlighted

how communities might have concerns around both being included and excluded from 229 vaccination target groups. For example, the inclusion of adults of reproductive age was 230 frequently associated with concerns that vaccines affected fertility. On the other hand, some 231 participants noted concerns from pregnant women about being initially excluded from 232 receiving the rVSV-ZEBOV vaccine. Younger adults, notably young males, were described 233 in both the literature and interviews as often being indifferent to meningitis A or yellow fever 234 235 vaccination; their perceived risk of contracting the disease or developing severe outcomes was low so they did not see the benefit of being vaccinated. Interview participants also 236 237 outlined how older adults sometimes needed convincing that it was worthwhile to vaccinate them in their stage of life. 238

"No, no, no, at my age," some will tell you, "at my age I think I'm just about due, [to
die]." ... [We use] persuasions in line with trying to make them valuable to society.
(National health agency and academia, East Africa)

Participants spoke of spending considerable time explaining the disease and the vaccine
development, safety, and regulatory processes to communities, along with why adults were
being targeted for vaccination. This type of meaningful engagement with communities is
critical to facilitate a better understanding of the disease and address community concerns
around vaccination target groups. However, participants noted that time and resources (e.g.,
staff, development of messages, training, transport, and per diems) are required for this

249

250 *Tailoring delivery strategies*

Tailored delivery strategies are required for groups that experience either physical or social barriers to accessing vaccination. For example, young adult males were sometimes unable to access vaccination sites due to work commitments during meningitis A campaigns. To

improve uptake, vaccination centres were positioned near facilities they frequented, such as 254 workplaces, hotels, restaurants, and transport hubs.[25] Social and cultural norms were also 255 identified as potential barriers to vaccination. During meningitis A campaigns in West Africa, 256 257 sociocultural beliefs sometimes prevented men from attending vaccination centres at the same time as women and children.[25] Similarly, one participant (Multilateral organisation, 258 East and West Africa) described how young married women might not be able to attend a 259 260 public vaccination site without authorisation from their spouses. Engaging with community leaders to map social groups and identify when, where, and how vaccination teams can most 261 262 effectively reach sub-groups is vital to achieving high vaccination coverage.

263

264 Integrating vaccination campaigns with other health services

Participants highlighted how accessing remote locations during vaccination campaigns can be 265 viewed as an important opportunity to provide other health services. Integrating multiple 266 vaccination campaigns can minimise time burdens on both communities and health workers 267 and can potentially increase uptake by offering additional health services that the community 268 prioritises. For example, one participant (National health agency, West Africa) described how 269 vaccination uptake in nomadic communities increased following the development of a 270 collaborative human-animal health initiative where vaccinations and health assessments for 271 community members and their livestock were conducted during the same visit. While some 272 273 participants viewed multi-service integration positively, they also mentioned challenges around the coordination and reporting of multiple activities. 274

275

Integrating COVID-19 vaccination with other services requires careful planning with
 communities to prevent potential spillover of COVID-19 vaccine hesitancy to other services.

In some settings, participants had already observed an adverse effect on the uptake of other
vaccines due to COVID-19.

Some [community members] are really against COVID-19 vaccination, they say "no,
you want to smuggle in the COVID-19 vaccine in the name of yellow fever." (National
health agency, West Africa)

Consequently, participants outlined how vaccination teams have had to differentiate between vaccines for COVID-19 and vaccines for other pathogens, reassuring communities that the dispensed vaccine was *not* a COVID-19 vaccine. This differentiation was seen to be the only way to ensure that the uptake of other vaccines was not compromised, but it adds to the complexity of messaging for COVID-19 vaccines.

288 **3) Logistics and supply**

289 *Vaccine storage and transportation*

Participants outlined how vaccine storage assessments were necessary before each campaign
and stressed how quickly capacity could change at the facility level, affecting product
viability. During meningitis A clinical trials, mock-up shipments of MenAfriVac were sent to
each country to test the supply chain and ensure the vaccines had been correctly handled
throughout their journey.[13] In-depth logistical planning exercises and simulations can help
identify and mitigate potential areas of vaccine wastage.[12, 48]

297 Subnational vaccine storage hubs that enable the rapid movement of supplies during a

298 campaign are critical to success, particularly in areas where it is difficult to estimate the target

299 population. Some vaccines (i.e., rVSV-ZEBOV, mRNA vaccines for COVID-19) require

300 ultra-cold chain (UCC) infrastructure. While centralised depots with reliable access to

301 electricity may seem most effective, some participants felt that centralisation led to

unacceptable delays. Increasing storage capacity and cold chain management at the
 subnational level was seen as a solution to ensure the timely distribution of vaccines during a
 campaign.

305

During EVD vaccine clinical trials, significant investments were made to ensure appropriate 306 UCC infrastructure was in place.[28] Interview participants believed that UCC was generally 307 308 well managed during EVD outbreaks. However, they also emphasised that qualified staff (e.g., pharmacists, consultants) were employed to manage this process during well-resourced 309 310 campaigns. Multi-dose vaccine vials simplified UCC storage and transport, requiring less space than single-dose vials, but one participant (NGO, Central Africa) noted how concerns 311 around vaccine wastage with multi-dose vials affected how vaccination teams interacted with 312 those waiting to be vaccinated. In some instances, vaccination teams would wait for sufficient 313 eligible persons to arrive before opening the vial to limit the risk of vaccine wastage. This 314 approach assumed that community members could wait, sometimes for hours, to receive their 315 vaccination. 316

317 [Vaccination teams] wouldn't open a vial until [enough] people were there ...

[community members] would arrive at 8 am and they would still be there at 4 pm,

319 waiting for the other people to turn up. And if [the vaccination team] didn't get

[enough] people they wouldn't open the vial and they would go away again. (NGO,

321 Central Africa)

4) Vaccination teams

323 *Recruiting, training, and resourcing vaccination teams*

Participants consistently referred to the importance of recruiting local health workers who have established links to the community, can speak the local language, and can leverage

existing rapport to increase uptake, rather than bringing in staff from other regions.

If we need healthcare people, we try to take the village nurses themselves, we train
them in the activity, and they go to meet the community. ... So training the local
community is very good, not finding the people in the capital and sending them to the
village. (Multilateral organisation, West and Central Africa)

However, local recruitment depends on the availability of skilled workers and may place additional workload on already overburdened staff. Seconding staff to vaccination activities can also adversely affect the quality and availability of routine health services. Participants referred to how the outbreak response 'industry' during EVD outbreaks drained the local health workforce, with staff leaving routine posts to gain higher salaries in the response.

336

Recruiting new graduates and recently retired health staff to support large-scale vaccination campaigns was a strategy identified in both the literature and interviews.[29] However, participants were wary of introducing a parallel system that potentially excludes existing, trusted frontline health workers from vaccination campaigns. Some participants also highlighted lengthy recruitment processes as a barrier to bringing on additional staff.

342

Provision of training for vaccination teams is an essential component of pre-campaign 343 activities, [12] but participants highlighted issues around training quality at the lower levels of 344 the frequently used 'cascade' or 'training-of-trainers' model. Training deficiencies are often 345 picked up and corrected in the field through supervision, participants outlined, but this is 346 347 resource intensive. The transition to remote training to comply with COVID-19 physical distancing guidelines has introduced additional barriers to training delivery; many settings 348 have limited access to hardware and stable internet. Participants also raised concerns 349 regarding the quality of training on practical skills through virtual methods. 350

351	Most people couldn't access the internet and use a virtual platform And when you
352	evaluate the performance [of the training], it is very low, because most people
353	couldn't attend it. (National health agency, East Africa)
354	Even when in-person training has been possible, physical distancing measures have reduced
355	the capacity of commonly used training facilities, thereby restricting the number of people
356	able to take part.
357	
358	Inadequate resourcing of vaccination teams and lengthy processes for distributing funding
359	were identified as additional barriers, with participants stating that it was unfair to expect
360	teams to perform without funding.
361	[The resources] must be available, and that is very key, available and handed to the
362	people that actually get involved, because if you are going to keep the team in the
363	field for the whole day and they don't have support or any money to get themselves a
364	drink or something to eat, it is going to have a negative effect. (National health
365	agency, East Africa)
366	5) Vaccination monitoring and safety surveillance
367	Locally led, integrated vaccination monitoring
368	The ability to link a person to their vaccination, any subsequent adverse events following
369	immunisation, and any breakthrough infections is an important aspect of vaccination
370	campaign monitoring and can increase community confidence by providing organised,

accurate information on the progress of the campaign. However, outside of clinical trials,

372 most interview participants described complex data aggregation processes where indicators

373 held in different datasets were collated and compared. Innovations in electronic case-based

- 374 surveillance systems, such as the use of QR codes and new modules to track immunisation
- 375 status and adverse events following immunisation, were mentioned by a small number of

376	participants in relation to COVID-19. Nevertheless, most of these systems still involved a
377	combination of entering data on paper in the field and subsequently inputting the data to
378	electronic systems at higher levels (i.e., district level). Parallel systems and limited
379	standardisation in data collection can severely hamper the analysis and operational use of
380	vaccination coverage, vaccine efficacy, and vaccine safety data.[27]
381	
382	Participants highlighted how limited access to data held by different organisations negatively

affected response efforts. In one example, a participant (NGO, Central Africa) reported that government health staff could not compare newly confirmed EVD cases against the records of those who had been vaccinated due to a lack of access to crucial datasets held by other organisations. Participants described tensions when governments were not sufficiently supported in the ownership, storage, access, and analysis of vaccination data, highlighting the importance of these elements for the success of campaigns.

6) Community engagement and social mobilisation

390 *Timing and approach of community engagement*

Community engagement and social mobilisation are vital components of a successful 391 vaccination campaign. Participants repeatedly raised the importance of having a clear strategy 392 for engaging with communities, with consistent messaging around the disease, the vaccine, 393 vaccination target groups, and adverse events following immunisation. Some participants 394 linked the success of meningitis A vaccination to the Meningitis Vaccine Project's detailed 395 communication plan, which was developed, implemented and refined over a few years. 396 Importantly, participants outlined, the objective of the Meningitis Vaccine Project's 397 398 communication plan was to build community awareness and expectation for the vaccine well in advance of the campaigns. 399

400	The population was very aware [of meningitis], they were really waiting for this
401	vaccine. When we did the [meningitis A] vaccination campaign the vaccination
402	centres opened at 8 am, but at 5 am people were already queuing to get the vaccine.
403	(Multilateral organisation, West, Central and East Africa)
404	While participants recognised that reactive vaccination campaigns face intense time
405	pressures, they insisted that community engagement should precede vaccination campaigns
406	by a minimum of one to two months. This lead-in time is necessary to develop relationships
407	with community members, respond to vaccination queries, and tailor delivery strategies.
408	
409	Participants stressed that early vaccine acceptance could not be taken as indicative of
410	community sentiment throughout a campaign. Continuous engagement with communities was
411	considered crucial to monitoring community acceptance, responding to concerns around
412	vaccine safety, and explaining the rationale behind target group selection. Reconnecting with
413	communities and providing feedback at the end of the campaign was also deemed essential in
414	enhancing trust and building sustainable relationships that would support future vaccine
415	uptake.
416	The feedback to the community leaders is very, very important, because we always
417	seek their permission, their help, their assistance, but we never give them feedback.
418	(Multilateral organisation, West Africa)
419	
420	Respect, honesty, and meaningful discussion were stressed as principles crucial to building
421	trust:
422	There are many things that the communities need to understand. They may not be
423	intellectual but they are not stupid. They observe and ask relevant questions. So one
424	of the keys is to never hide the truth. Be frank and honest with them, because when they

425 trust you, they trust you forever. But when you lose [their] confidence, it's difficult.

426 (Multilateral organisation, West and Central Africa)

427 Communities want to actively participate in discussions about the need for, or benefit of, new 428 vaccines.[44] Providing community members with an opportunity to ask questions and query 429 points about the disease or vaccine is a crucial enabler for vaccination success. Participants 430 outlined how engaged community members often became champions for the campaign.

431

Participants affirmed that vaccines for well-known and feared diseases, like meningitis A and
yellow fever, generally had high community uptake, but social mobilisation was much more
difficult if diseases were not known or prioritised by communities. Generating demand for
vaccination where communities had other priorities outside the health sector was particularly
challenging.

437 [Community members] would say "What we need is a bridge, we need a road to be
438 repaired. ... When you have those things, bring the [vaccination] request." (National
439 health agency, West Africa)

Addressing this challenge, participants said, required detailed and focused communication
about the disease beyond simple vaccine uptake advocacy; working with communities to
ensure they had appropriate information to understand the disease, its severity, and the
burden on their communities.[44] Data on disease incidence is critical to these discussions.
Some participants highlighted concerns that limited COVID-19 case detection in African
countries would negatively impact community perceptions of disease burden and the need for
vaccination.

447

The current limited supply of COVID-19 vaccines presents a paradox for LMICs in terms of
 community engagement and social mobilisation. While delayed vaccine delivery means

countries have more time to plan mobilisation activities, they lack the operational funding
required to design and deliver these activities. Further, generating demand in the face of
limited supply requires careful balancing of risks; some participants spoke of how they had
not yet employed previously used demand generation methods, such as SMS alerts, for
COVID-19 for fear of overwhelming their limited vaccine supply.

455 **7) Vaccine confidence**

456 *Responding to vaccine concerns*

457 Swift, transparent and trusted responses are needed to address vaccine concerns. Participants stated that the longer a rumour circulates, the greater the risk to a vaccination campaign. 458 Influencers — political, religious, and traditional leaders or heads of social groups (e.g., 459 460 women's groups, youth groups, or sporting groups) — play an important role in counteracting negative rumours. When rumours were spread by a prominent individual, such 461 as a religious leader, participants described using a similarly influential person to counter 462 those messages. Rumours spread by health professionals were especially difficult to address 463 and were best responded to by other health professionals. National Immunisation Technical 464 465 Advisory Groups can also play a role in fostering community confidence and dispelling 466 rumours by providing independent, evidence-based information on the disease and the vaccination campaign. 467

468

Vaccine hesitancy in the COVID-19 response was perceived as particularly challenging
compared to previous campaigns. Participants attributed this to the global nature of the
pandemic and the propagation of rumours through social media.

472 The problem is that COVID-19 is too publicised, which is already a major obstacle to 473 acceptance. ... Unfortunately today, the world cannot control [the information]

474	because everyone has become an expert in COVID-19 vaccination or an expert in
475	COVID-19. (Multilateral organisation, West and Central Africa)
476	Several participants described how social media tracking and online rumour debunking were
477	incorporated into their COVID-19 response activities. Some countries have partnered with
478	social media and technology companies to provide accurate information through their
479	messaging forums. However, other participants described this as a weaker area of their
480	response, highlighting that further investment was needed to counter the proliferation of
481	misinformation and rumours. While participants described the unique challenge of rumours
482	circulating on social media, they also stressed the importance of continued face-to-face
483	interaction with communities to understand and respond to rumours in-person rather than
484	relying on information distributed online.
485	
486	Participants noted that rumours around 'vaccine testing' were prevalent in both the EVD and
487	COVID-19 responses, but that community risk perceptions were different between the
488	campaigns.
489	[During the EVD response] there was lots of talk about being guinea pigs and
490	[people] would say, "yeah, we're guinea pigs", but a lot of people went, "actually, I'd
491	rather be a guinea pig and get vaccinated than get Ebola." Early on in the COVID-
492	19 outbreak [the population] said, "well, we're not willing to be guinea pigs for this
493	one because it's not our problem we are probably not going to die of COVID-19."
494	(NGO, Central Africa)
495	Participants spoke of how they explained the vaccine regulatory and approval processes to
496	communities, highlighting that COVID-19 vaccine trials had already been conducted in other
497	countries outside of Africa. However, changing community perceptions was considered

498	difficult due to misinformation and the absence of high disease incidence or severity that
499	might increase the prioritisation of COVID-19 vaccination within communities.

500 **DISCUSSION**

- 501 This research took place as the first doses of COVID-19 vaccines provided through COVAX
- ⁵⁰² arrived in LMICs in Africa and South America. We reviewed the literature and interviewed
- 503 technical experts with extensive experience in epidemic vaccination campaigns to develop
- recommendations for the rollout of COVID-19 vaccines in LMICs. Table 4 presents a set of
- recommendations. Key recommendations include: prioritising time, funding and workforce
- 506 for community engagement; identifying effective training strategies to upskill vaccination
- 507 teams; streamlining response coordination and vaccination monitoring functions; and
- 508 exploring opportunities for health service integration.

510 **TABLE 4: Recommendations for the implementation of COVID-19 vaccines in LMICs,**

511 based on lessons from meningitis A, yellow fever and Ebola virus disease vaccination

512 campaigns

Recommendation	Domains
Prioritise the availability of operational funds to support community engagement and social mobilisation well in advance of vaccination activities.	 Planning and coordination Community engagement and social mobilisation
Develop a community engagement strategy that emphasises the principles of community involvement, co-development, and iterative adaptation. Vaccination teams should meet iteratively with community members, actively seek their questions and input on strategy development, and adapt vaccination strategies accordingly.	 Community engagement and social mobilisation Target groups and delivery strategies Vaccine confidence
Engage local, trusted health workers (including Community Health Workers) to support vaccination activities, ensuring a continued connection between communities and the vaccination campaign.	Vaccination teamsCommunity engagement and social mobilisation
Develop rapid processes to recruit and manage an expanded vaccination workforce for the response. Care should be taken to balance response staffing requirements with the need to maintain existing services.	• Vaccination teams
Evaluate and refine training strategies to ensure vaccination teams are well equipped to conduct vaccination activities. Identify teams who are not able to access remote training and design suitable alternatives.	• Vaccination teams
Provide vaccination teams with clear guidance on the management of multi-dose vaccine vials, including which population groups should be offered leftover vaccine doses where the vial cannot be appropriately stored and used at a later time.	Vaccination teamsLogistics and supply
Ensure national ownership, access and capacity to analyse vaccination campaign data, including the use of electronic data capture systems.	• Vaccination monitoring and safety surveillance
Work with technical leads across the outbreak response (e.g., surveillance, vaccination) to streamline the collection, aggregation and analysis of different indicators to support vaccination campaign monitoring.	• Vaccination monitoring and safety surveillance
Bring together response pillar leads and routine health programme leads to discuss opportunities to integrate health services during vaccination campaigns. Any integration of services should be well resourced, and well coordinated between services and with communities, to mitigate potential adverse impacts.	• Target groups and delivery strategies

To date, gaps in operational funding for COVID-19 vaccination campaigns in LMICs have
prevented some vaccination teams from conducting crucial community engagement activities.
Mobilising communities in the face of limited COVID-19 vaccine supply is a difficult
balance. Nevertheless, while waiting for sufficient vaccines to be delivered, countries can
involve communities in the proposed rollout, listen to their concerns and devise solutions. It
is crucial that countries prioritise operational funds to support vaccination teams to
effectively conduct these preparatory activities.

521

522 There are several advantages to employing local health workers in vaccination campaigns. Building on existing trust and rapport, local health workers can engage with communities, 523 discuss key information about the campaign, monitor vaccine acceptance levels and respond 524 525 to rumours as they arise. In order to employ local health workers that are not yet supporting the COVID-19 response, countries must identify mechanisms to rapidly recruit and train 526 them. Evidence around effective training strategies for health workers in LMICs during 527 epidemics remains limited.[49, 50] While the 'cascade' or 'training-of-trainers' model is seen 528 as economical and rapidly scalable, [51] participants highlighted issues of quality as 529 information is transmitted to lower levels. Considering the key role health workers play in 530 mobilising communities and delivering vaccinations, countries must evaluate and refine 531 training strategies to effectively upskill their vaccination teams for COVID-19. 532

533

Co-administration of COVID-19 with other vaccines is not currently recommended by the
WHO Strategic Advisory Group of Experts on Immunization,[52] preventing potential
efficiency gains through integration. While integration can reduce time and cost burdens, it
introduces challenges around coordination, reporting, and staff capacity.[53] Further,
COVID-19 vaccine hesitancy may affect the uptake of other vaccines. The differentiation

between COVID-19 and other vaccines has perpetuated the belief that some vaccines are safe 539 while others are not. Without a concerted effort to change community perceptions around 540 COVID-19 vaccines, integrating other campaigns with COVID-19 vaccination is unlikely to 541 yield high uptake. Integrating other community-prioritised health services (e.g., antenatal 542 care) may be a more effective strategy. Careful planning with other health programmes and 543 communities is needed to identify and mitigate the potential effect of COVID-19 vaccine 544 545 hesitancy on other services. Considering the significant impact of COVID-19 on access to routine health services in LMICs, [54, 55] the integration of services should be discussed and 546 547 pursued where appropriate.

548

Most COVID-19 vaccines currently under Emergency Use Listing (EUL) by WHO are 549 packaged in multi-dose vials.[21, 56] Multi-dose vaccine vials are widely used in LMICs as 550 they are cheaper and require less storage space. [57] However, health workers' reluctance to 551 open multi-dose vials for fear of vaccine wastage was identified in this research and has also 552 been reported for routine immunisation programmes in LMICs. [21, 56] The limited supply of 553 COVID-19 vaccines is likely to increase pressure on vaccination teams to minimise wastage, 554 which may be complicated by the strict prioritisation of target groups and instances where 555 sufficient eligible persons do not present for vaccination. To minimise wastage and reduce 556 557 the risk of loss-to-follow up, vaccination teams should be given clear guidelines for 558 administering the remaining doses in multi-dose vials to persons outside of priority groups. 559 Incident management systems provide direction and coordination across response activities, 560 including vaccination. However, the unprecedented scale and extended duration of the 561

COVID-19 pandemic has placed enormous pressure on key personnel within response

562

structures. The incident management system model is labour intensive.[58, 59] While there 563

has been a global recognition of frontline worker burnout, the effect of a protracted pandemic
on key personnel in countries' incident management systems should also be considered.[60]
Countries need to explore ways to streamline coordination processes and upskill additional
staff to fulfil IMS functions to ensure continuity in the response.

568

569 Due to the geographical distribution of the selected diseases and the distribution of the 570 research team's professional networks, this research draws primarily from vaccine 571 implementation experiences in LMICs in West, Central and East Africa. The findings may 572 not be generalisable to other geographic areas, which are likely to have their own set of 573 challenges in implementing vaccines. In addition, several identified technical experts could 574 not participate due to competing priorities, including the COVID-19 response and the EVD 575 outbreaks in the first half of 2021.

576

577 CONCLUSION

These recommendations rely on LMICs having sufficient vaccine supply to conduct vaccination campaigns for COVID-19, which has not been the case in most settings. We implore the global community to prioritise COVID-19 vaccine supply for LMICs. As vaccine supplies increase, we encourage researchers to support countries in monitoring and documenting their COVID-19 vaccination campaigns to understand real-time responses to challenges and strengthen evidence around best practices during outbreak-related vaccination campaigns in low-resource settings.

586 Acknowledgements

587 The authors would like to thank the technical experts who took time out of their busy

- schedules in the midst of the COVID-19 pandemic and concurrent outbreaks to give
- interviews and who generously shared their experiences, knowledge and insights to support
- 590 this research.
- 591

592 Contributors

- All authors provided input into the conceptualisation of the study and its design. The
- interviews and qualitative analysis were conducted by J.C and R.W with support from D.K.
- 595 The literature review was conducted by D.K with support from K.N and J.C. The manuscript
- 596 was prepared by J.C and D.K. All authors provided input into the manuscript and are
- 597 guarantors of the study.

598

599 Funding

- 600 This research was funded by UK Aid from the Department of Health and Social Care (https://
- 601 www.gov.uk/government/collections/officialdevelopment-assistance-oda-2, Grant No. IS-
- 602 RRT-1015-001) via the UK Public Health Rapid Support Team Research Programme. The
- 603 UK Public Health Rapid Support Team is funded by UK Aid from the Department of Health
- and Social Care and is jointly run by Public Health England and the London School of
- 605 Hygiene & Tropical Medicine. The views expressed in this publication are those of the
- author(s) and not necessarily those of the Department of Health and Social Care.

607

- 608 Competing interests
- None declared.

610

- 611 Patient consent
- 612 Not required.

613

614 Ethics approval

The study was approved by the London School of Hygiene & Tropical Medicine Research

616 Ethics Committee (ref: 24044).

618 **Provenance and peer review**

- 619 Not commissioned; externally peer reviewed.
- 620

621 Data sharing statement

- 622 The qualitative data generated through this study are not suitable for sharing beyond that
- 623 contained within the manuscript in order to protect participants' anonymity. Further
- 624 information can be obtained from the corresponding author.

625 **REFERENCES**

626 1. Skegg D, Gluckman P, Boulton G, et al. Future scenarios for the COVID-19 pandemic. The Lancet. 2021;397(10276):777-8. 627 The Lancet Microbe. COVID-19 vaccines: the pandemic will not end overnight. 628 2. 629 *Lancet Microbe*. 2021;2(1):e1-e. So AD, Woo J. Reserving coronavirus disease 2019 vaccines for global access: cross 630 3. sectional analysis. BMJ. 2020;371:m4750. 631 Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 4. 632 vaccinations. Nature Human Behaviour. 2021. 633 World Health Organization. COVAX Announces additional deals to access promising 5. 634 COVID-19 vaccine candidates; plans global rollout starting Q1 2021 2020. Available from: 635 https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-636 promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021. [Accessed on 637 25 January, 2021]. 638 Guignard A, Praet N, Jusot V, et al. Introducing new vaccines in low- and middle-639 6. income countries: challenges and approaches. Expert Review of Vaccines. 2019;18(2):119-31. 640 Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of 641 7. 642 COVID-19 vaccine in low-income countries. npj Vaccines. 2021;6(1):54. World Health Organization. Global Ebola Vaccine Implementation Team 643 8. (GEVIT)Practical guidance on the use of Ebola vaccine in an outbreak response. 2016. 644 645 9. Ebola vaccine deployment aacEc. Ebola vaccine communication, community engagement and compliance management (3C) gap analysis tool. 2019. 646 World Health Organization, UNICEF. Guidance on developing a national deployment 10. 647 648 and vaccination plan for COVID-19 vaccines: Interim guidance. 2020. Aguado MT, Jodar L, Granoff D, et al. From epidemic meningitis vaccines for Africa 11. 649 to the meningitis vaccine project. Clinical Infectious Diseases. 2015;61(Supplement 5):S391-650 S5. 651 12. Burchett HED, Mounier-Jack S, Torres-Rueda S, et al. The impact of introducing new 652 653 vaccines on the health system: Case studies from six low- and middle-income countries. Vaccine. 2014;32(48):6505-12. 654 Marchetti E, Mazarin-Diop V, Chaumont J, et al. Conducting vaccine clinical trials in 655 13. sub-Saharan Africa: Operational challenges and lessons learned from the Meningitis Vaccine 656 Project. Vaccine. 2012;30(48):6859-63. 657 658 14. Zipursky S, Djingarey MH, Lodjo JC, et al. Benefits of using vaccines out of the cold chain: Delivering Meningitis A vaccine in a controlled temperature chain during the mass 659 immunization campaign in Benin. Vaccine. 2014:32(13):1431-5. 660 661 15. Djingarey MH, Barry R, Bonkoungou M, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience. Vaccine. 662 2012;30:B40-B5. 663 664 16. Cibrelus L, Lingani C, Fernandez K, et al. Risk Assessment and Meningococcal A Conjugate Vaccine Introduction in Africa: The District Prioritization Tool. Clin Infect Dis. 665 2015;61 Suppl 5(Suppl 5):S442-50. 666 667 17. Okwo-Bele JM, Cherian T. The expanded programme on immunization: A lasting legacy of smallpox eradication. Vaccine. 2011;29(SUPPL. 4):D74-D9. 668 Tartof S, Cohn A, Tarbangdo F, et al. Identifying Optimal Vaccination Strategies for 18. 669 Serogroup A Neisseria meningitidis Conjugate Vaccine in the African Meningitis Belt. PLOS 670 ONE. 2013;8(5):e63605. 671


19. Mbaeyi S, Sampo E, Dinanibe K, et al. Meningococcal carriage 7 years after 672 introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from 673 four cross-sectional carriage surveys. The Lancet Infectious diseases. 2020;20(12):1418-25. 674 20. Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal 675 676 conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: A community study. The Lancet. 2014;383(9911):40-7. 677 21. Nkwenkeu SF, Jalloh MF, Walldorf JA, et al. Health workers' perceptions and 678 679 challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule in Burkina Faso. BMC public health. 2020;20(1):254. 680 Patel JC, Soeters HM, Diallo AO, et al. MenAfriNet: A Network Supporting Case-681 22. 682 Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa. Journal of Infectious Diseases. 2019;220(Supplement 4):S148-S54. 683 684 23. Diomande FVK, Djingarey MH, Daugla DM, et al. Public health impact after the 685 introduction of PsA-TT: The first 4 years. Clinical Infectious Diseases. 2015;61(Supplement 5):S467-S72. 686 Berlier M, Barry R, Shadid J, et al. Communication Challenges During the 687 24. 688 Development and Introduction of a New Meningococcal Vaccine in Africa. Clinical Infectious Diseases. 2015;61(suppl 5):S451-S8. 689 25. Djingarev MH, Diomandé FV, Barry R, et al. Introduction and Rollout of a New 690 Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 691 2010-2014. Clin Infect Dis. 2015;61 Suppl 5(Suppl 5):S434-41. 692 Ughasoro MD, Esangbedo DO, Tagbo BN, et al. Acceptability and willingness-to-pay 693 26. for a hypothetical ebola virus vaccine in Nigeria. PLoS Neglected Tropical Diseases. 694 695 2015;9(6):e0003838. 27. Wolf J, Bruno S, Eichberg M, et al. Applying lessons from the Ebola vaccine 696 experience for SARS-CoV-2 and other epidemic pathogens. npj Vaccines. 2020;5(1):51. 697 Jusu MO, Glauser G, Seward JF, et al. Rapid Establishment of a Cold Chain Capacity 698 28. of -60°C or Colder for the STRIVE Ebola Vaccine Trial During the Ebola Outbreak in Sierra 699 Leone. The Journal of infectious diseases. 2018;217(suppl 1):S48-S55. 700 29. 701 Samai M, Seward JF, Goldstein ST, et al. The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSVDELTAG-ZEBOV-GP Vaccine Tolerability 702 703 and Safety during the West Africa Ebola Outbreak. Journal of Infectious Diseases. 2018;217(Supplement 1):S6-S15. 704 Dean NE, Gsell PS, Brookmeyer R, et al. Design of vaccine efficacy trials during 705 30. 706 public health emergencies. Science Translational Medicine. 2019;11(499). 707 31. Hossmann S, Haynes AG, Spoerri A, et al. Data management of clinical trials during an outbreak of Ebola virus disease. Vaccine. 2019;37(48):7183-9. 708 32. Grantz KH, Claudot P, Kambala M, et al. Factors influencing participation in an 709 710 Ebola vaccine trial among front-line workers in Guinea. Vaccine. 2019;37(48):7165-70. Juan-Giner A, Tchaton M, Jemmy JP, et al. Safety of the rVSV ZEBOV vaccine 711 33. against Ebola Zaire among frontline workers in Guinea. Vaccine. 2019;37(48):7171-7. 712 Elemuwa C, Kutalek R, Ali M, et al. Global lessons from Nigerias ebolavirus control 713 34. strategy. Expert Review of Vaccines. 2015;14(11):1397-400. 714 715 Alenichev A, Peeters Grietens K, Gerrets R. Conceptions within misconceptions: 35. 716 Pluralisms in an Ebola vaccine trial in West Africa. Global Public Health. 2020;15(1):13-21. Folayan MO, Yakubu A, Haire B, et al. Ebola vaccine development plan: ethics, 717 36. concerns and proposed measures. BMC Medical Ethics. 2016;17(1):10. 718 719 Tomashek K, Challberg M, Nayak S, et al. Disease Resurgence, Production 37. Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a 720 Need for a New Yellow Fever Vaccine? Vaccines. 2019;7. 721

38. Chen LH, Hamer DH. Vaccination Challenges in Confronting the Resurgent Threat 722 From Yellow Fever. Jama. 2017;318(17):1651-2. 723 Vannice K, Wilder-Smith A, Hombach J. Fractional-Dose Yellow Fever Vaccination 724 39. — Advancing the Evidence Base. New England Journal of Medicine. 2018;379(7):603-5. 725 Barrett ADT. Yellow Fever in Angola and Beyond — The Problem of Vaccine 726 40. Supply and Demand. New England Journal of Medicine. 2016;375(4):301-3. 727 41. Possas C, Lourenco-de-Oliveira R, Tauil PL, et al. Yellow fever outbreak in Brazil: 728 the puzzle of rapid viral spread and challenges for immunisation. Memorias do Instituto 729 730 Oswaldo Cruz. 2018;113(10):e180278. 731 42. Martins RM, Maia MdLS, Farias RHG, et al. 17DD yellow fever vaccine. Human Vaccines & Immunotherapeutics. 2013;9(4):879-88. 732 Flamand C, Bailly S, Fritzell C, et al. Vaccination coverage in the context of the 733 43. 734 emerging Yellow Fever threat in French Guiana. PLoS Neglected Tropical Diseases. 735 2019;13(8):e0007661. Legesse M, Endale A, Erku W, et al. Community knowledge, attitudes and practices 736 44. on Yellow fever in South Omo area, Southern Ethiopia. PLoS neglected tropical diseases. 737 738 2018;12(4):e0006409. Nguyen T, Richardson S. Vaccine stockpile governance through partnership: The 739 45. International Coordination Group on Emergency vaccine provision and its impacts. 740 741 International Journal of Infectious Diseases. 2019;79(Supplement 1):132-3. Yakum MN, Ateudjieu J, Walter EA, et al. Vaccine storage and cold chain monitoring 742 46. 743 in the North West region of Cameroon: a cross sectional study. BMC Research Notes. 744 2015;8(1):145. Sow C, Sanou C, Medah C, et al. Challenges of cold chain quality for routine EPI in 745 47. south-west Burkina-Faso: An assessment using automated temperature recording devices. 746 747 Vaccine. 2018;36(26):3747-55. Kochhar S, Rath B, Seeber LD, et al. Introducing new vaccines in developing 748 48. countries. Expert Rev Vaccines. 2013;12(12):1465-78. 749 750 49. Navahangan LJ, Konge L, Russell L, et al. Training and education of healthcare workers during viral epidemics: a systematic review. BMJ Open. 2021;11(5):e044111. 751 752 Rowe AK, Rowe SY, Peters DH, et al. The effectiveness of training strategies to 50. improve healthcare provider practices in low-income and middle-income countries. BMJ 753 754 Global Health. 2021;6(1):e003229. 755 Mormina M, Pinder S. A conceptual framework for training of trainers (ToT) 51. 756 interventions in global health. Globalization and Health. 2018;14(1):100. 52. 757 World Health Organization. Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing. 2021. 758 759 53. Mounier-Jack S, Mayhew SH, Mays N. Integrated care: learning between high-760 income, and low- and middle-income country health systems. Health policy and planning. 2017;32(suppl_4):iv6-iv12. 761 Roberton T, Carter ED, Chou VB, et al. Early estimates of the indirect effects of the 762 54. COVID-19 pandemic on maternal and child mortality in low-income and middle-income 763 countries: a modelling study. The Lancet Global Health. 2020;8(7):e901-e8. 764 Dixit SM, Sarr M, Gueye DM, et al. Addressing disruptions in childhood routine 765 55. immunisation services during the COVID-19 pandemic: perspectives from Nepal, Senegal 766 and Liberia. BMJ Global Health. 2021;6(7):e005031. 767 Krudwig K, Knittel B, Karim A, et al. The effects of switching from 10 to 5-dose 768 56. 769 vials of MR vaccine on vaccination coverage and wastage: A mixed-method study in Zambia. Vaccine. 2020;38(37):5905-13. 770

57. Drain PK, Nelson CM, Lloyd JS. Single-dose versus multi-dose vaccine vials for 771 immunization programmes in developing countries. Bulletin of the World Health 772 773 Organization. 2003:81(10):726-31. Richard B, Robert H, Paul C, et al. Adapting the Incident Management System for 774 58. 775 response to health emergencies - early experience of WHO. Weekly epidemiological record. 2018;93(20):279-83. 776 777 Olu OO, Lamunu M, Chimbaru A, et al. Incident Management Systems Are Essential 59. 778 for Effective Coordination of Large Disease Outbreaks: Perspectives from the Coordination 779 of the Ebola Outbreak Response in Sierra Leone. Front Public Health. 2016;4:254-. 780 Deng D, Naslund JA. Psychological Impact of COVID-19 Pandemic on Frontline 60. Health Workers in Low- and Middle-Income Countries. Harv Public Health Rev (Camb). 781 2020;28. 782 783 61. World Health Organization. Vaccines and vaccination against yellow fever. WHO 784 position paper. 2013. World Health Organization. Meningococcal vaccines: WHO position paper. 2011. 785 62. World Health Organization. WHO position paper, Meningococcal A conjugate 786 63. 787 vaccine: Updated guidance, February 2015. Weekly Epidemiological Record. 2015;8(90):57-788 68. 64. World Health Organization. WHO pregualifies Ebola vaccine, paving the way for its 789 790 use in high-risk countries 2019. Available from: https://www.who.int/news/item/12-11-2019who-prequalifies-ebola-vaccine-paving-the-way-for-its-use-in-high-risk-countries. [Accessed 791 792 on 19 April, 2021]. 793 Bache BE, Grobusch MP, Agnandji ST. Safety, immunogenicity and risk-benefit 65. analysis of rVSV-AG-ZEBOV-GP (V920) Ebola vaccine in Phase I-III clinical trials across 794 regions. Future Microbiology. 2020;15(2):85-106. 795 796 World Health Organization. Ebola virus disease: Vaccines 2020. Available from: 66. 797 https://www.who.int/news-room/q-a-detail/ebola-vaccines. [Accessed on 11 July, 2021]. World Health Organization. Community engagement: a health promotion guide for 798 67. universal health coverage in the hands of the people . 2020. 799 800 68. World Health Organization. Communication for behavioural impact: A toolkit for

behavioural and social communication in outbreak response.; 2012.

802



805 FIGURE 1: Literature review flowchart